TY - JOUR
T1 - Specialist versus Primary Care Prostate Cancer Follow-Up
T2 - A Process Evaluation of a Randomized Controlled Trial
AU - Wollersheim, Barbara M.
AU - van Asselt, Kristel M.
AU - Pos, Floris J.
AU - Akdemir, Emine
AU - Crouse, Shifra
AU - van der Poel, Henk G.
AU - Aaronson, Neil K.
AU - van de Poll-Franse, Lonneke V.
AU - Boekhout, Annelies H.
N1 - Funding Information: Funding: This work is funded by the Dutch Cancer Society (Delfandlaan 17, 1062 EA, Amsterdam, The Netherlands), grant number NKI 2015-7932. Publisher Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/7/1
Y1 - 2022/7/1
N2 - Background: A randomized controlled trial (RCT) is currently comparing the effectiveness of specialist-versus primary care-based prostate cancer follow-up. This process evaluation assesses the reach and identified constructs for the implementation of primary care-based follow-up. Methods: A mixed-methods approach is used to assess the reach and the implementation through the Consolidated Framework for Implementation Research. We use quantitative data to evaluate the reach of the RCT and qualitative data (interviews) to indicate the perspectives of patients (n = 15), general practitioners (GPs) (n = 10), and specialists (n = 8). Thematic analysis is used to analyze the interview transcripts. Results: In total, we reached 402 (67%) patients from 12 hospitals and randomized them to specialist-(n = 201) or to primary care-based (n = 201) follow-up. From the interviews, we identify several advantages of primary care-versus specialist-based follow-up: it is closer to home, more accessible, and the relationship is more personal. Nevertheless, participants also identified challenges: guidelines should be implemented, communication and collaboration between primary and secondary care should be improved, quality indicators should be collected, and GPs should be compensated. Conclusion: Within an RCT context, 402 (67%) patients and their GPs were willing to receive/provide primary care-based follow-up. If the RCT shows that primary care is equally as effective as specialist-based follow-up, the challenges identified in this study need to be addressed to enable a smooth transition of prostate cancer follow-up to primary care.
AB - Background: A randomized controlled trial (RCT) is currently comparing the effectiveness of specialist-versus primary care-based prostate cancer follow-up. This process evaluation assesses the reach and identified constructs for the implementation of primary care-based follow-up. Methods: A mixed-methods approach is used to assess the reach and the implementation through the Consolidated Framework for Implementation Research. We use quantitative data to evaluate the reach of the RCT and qualitative data (interviews) to indicate the perspectives of patients (n = 15), general practitioners (GPs) (n = 10), and specialists (n = 8). Thematic analysis is used to analyze the interview transcripts. Results: In total, we reached 402 (67%) patients from 12 hospitals and randomized them to specialist-(n = 201) or to primary care-based (n = 201) follow-up. From the interviews, we identify several advantages of primary care-versus specialist-based follow-up: it is closer to home, more accessible, and the relationship is more personal. Nevertheless, participants also identified challenges: guidelines should be implemented, communication and collaboration between primary and secondary care should be improved, quality indicators should be collected, and GPs should be compensated. Conclusion: Within an RCT context, 402 (67%) patients and their GPs were willing to receive/provide primary care-based follow-up. If the RCT shows that primary care is equally as effective as specialist-based follow-up, the challenges identified in this study need to be addressed to enable a smooth transition of prostate cancer follow-up to primary care.
KW - consolidated framework for implementation research
KW - follow-up care
KW - general practice
KW - primary health care
KW - process evaluation
KW - prostate cancer survivors
UR - http://www.scopus.com/inward/record.url?scp=85132881281&partnerID=8YFLogxK
U2 - https://doi.org/10.3390/cancers14133166
DO - https://doi.org/10.3390/cancers14133166
M3 - Article
C2 - 35804937
SN - 2072-6694
VL - 14
JO - Cancers
JF - Cancers
IS - 13
M1 - 3166
ER -